APL-130277: Clinical Trials

6 trials of APL-130277, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 3 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3
Phase 33Completed 3

Follow APL-130277: new trials by email Literature Review of APL-130277 trials Research Report on APL-130277

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
APL-130277, subcutaneous apomorphine - Motor OFF Episodes Associated With Parkinson's Disease
Phase 3CompletedSumitomo Pharma America, Inc.1132018-12-192022-12-16
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
APL-130277, APO-go, Apokyn - Parkinson Disease
Phase 2CompletedSumitomo Pharma America, Inc.82017-08-222020-08-13
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
APL-130277, Placebo, Moxifloxacin - Parkinson's Disease, Off Episodes of Parkinson Disease
Phase 2CompletedSumitomo Pharma America, Inc.482017-08-032020-08-10
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
APL-130277 - Parkinson Disease
Phase 3CompletedSumitomo Pharma America, Inc.4962015-08-312023-11-22
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
APL-130277, Placebo - Parkinson Disease, Off Episodes
Phase 3CompletedSumitomo Pharma America, Inc.1412015-06-182020-07-30
A Study to Examine APL-130277 in Patients With Parkinson's Disease
APL-130277 - Parkinson's Disease
Phase 2CompletedSumitomo Pharma America, Inc.202014-08-312020-07-30

Conditions studied

Parkinson Disease (6)

Sponsors

Sumitomo Pharma America, Inc. (6)

Countries

United States (5)  ·  Italy (3)  ·  Austria (2)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Spain (2)  ·  United Kingdom (2)

Results publications

PMID 31818699, PMID 33991326, PMID 35899977

NIH funding

2016 (3)